← All trials
NCT05244057
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 23, 2022
- Primary completion
- Aug 31, 2024
- Completion date
- Aug 31, 2024
- First posted
- Feb 17, 2022
- Last posted
- Dec 13, 2022
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai HEP Pharmaceatical Co., Ltd.Lead sponsor
- Huazhong University of Science and TechnologyCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.